睿知中国医院研究地图
候选清单

正在招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

ARX788 in HER2-positive Metastatic Breast Cancer Patients

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由河南省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方河南省肿瘤医院Henan Cancer Hospital郑州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06663748,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Has recovered from any AE (≤ Grade 1) related to prior surgery and prior cancer treatment;

    入选标准第 6 条

    Has received any systemic anti-tumor therapy (with the exception of endocrine therapy, with an interval of at least 7 days) within 28 days (or at least 5 half-lives) before the first use of the investigational product;

    排除标准第 12 条

  3. ECOG Performance Status Score of 0-1;

    入选标准第 8 条

  4. Has at least one measurable target lesion as per RECIST1.1 criteria;

    入选标准第 5 条

  5. Breastfeeding female, or who has childbearing potential with a positive baseline pregnancy test or who is unwilling to use effective contraception during the trial;

    排除标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06663748,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 18 to 75 years old (including upper and lower limits), male or female;
  2. Unresectable locally advanced, recurrent or metastatic BC;
  3. Has previously received ≤ two lines of chemotherapy (excluding hormone therapy) for recurrent or metastatic BC;
  4. Tissue samples determined to be HER2 positive (defined as IHC3+ or FISH+);
  5. Has at least one measurable target lesion as per RECIST1.1 criteria;
  6. Has recovered from any AE (≤ Grade 1) related to prior surgery and prior cancer treatment;
  7. Adequate bone marrow, liver, kidney and coagulation function;
  8. ECOG Performance Status Score of 0-1;
  9. Voluntarily sign the informed consent, have good compliance and are willing to comply with the follow-up visit.

排除标准:Exclusion Criteria:

  1. Has known history to be allergic to any active ingredient or excipient of ARX788;
  2. With meningeal metastases or disseminated brain metastases or active brain metastases, who need radiation, surgery or drug therapy;
  3. Has pericardial effusion, pleural effusion or ascites effusion with clinical symptoms, signs or require symptomatic treatment;
  4. Has interstitial lung disease requiring steroid therapy, a history of drug-induced interstitial lung disease, a history of radiation pneumonitis, or any evidence indicating clinically active interstitial lung disease;
  5. Has any eye disease that require medical intervention such as keratitis, corneal diseases or active eye infection;
  6. Has cardiac insufficiency;
  7. Uncontrolled hypertension;
  8. Has evidence of severe or uncontrollable systemic diseases;
  9. Received live vaccines within 4 weeks before the first use of the investigational product or plans to receive live vaccines during the trial;
  10. Breastfeeding female, or who has childbearing potential with a positive baseline pregnancy test or who is unwilling to use effective contraception during the trial;
  11. Is unwilling or unable to stop wearing corneal contact lens during the trial;
  12. Has received any systemic anti-tumor therapy (with the exception of endocrine therapy, with an interval of at least 7 days) within 28 days (or at least 5 half-lives) before the first use of the investigational product;
  13. Has any mental or cognitive disorder that may restrict his/her understanding and execution of the informed consent form;
  14. Other conditions that the Investigator considers inappropriate for participation in this trial, such as poor compliance.

引自 ClinicalTrials.gov, NCT06663748, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06663748,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06663748